deltatrials
Unknown OBSERVATIONAL NCT02362620

PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. (PROSTAC)

Prospective Multi-centre Study of Prognostic Factors in Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel or Cabazitaxel.

Sponsor: Centro Nacional de Investigaciones Oncologicas CARLOS III

Conditions Advanced Prostate Cancer Cabazitaxel Docetaxel
Updated 16 times since 2017 Last updated: Jan 23, 2020 Started: May 31, 2014 Primary completion: Apr 30, 2018 Completion: Dec 31, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Advanced Prostate Cancer and Cabazitaxel and is currently ongoing. Centro Nacional de Investigaciones Oncologicas CARLOS III leads this study, which shows 16 recorded versions since 2014 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Apr 2017 · 3 months · monthly snapshot~Apr 2017 – ~Aug 2017 · 4 months · monthly snapshot~Aug 2017 – ~Mar 2018 · 7 months · monthly snapshot~Mar 2018 – ~Apr 2018 · 31 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Feb 2020 · 11 months · monthly snapshot~Feb 2020 – ~Nov 2020 · 9 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Mar 2022 · 3 months · monthly snapshot~Mar 2022 – ~Jul 2024 · 28 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

16 versions recorded

  1. Sep 2025 — Present [monthly]

    Unknown

  2. Sep 2024 — Sep 2025 [monthly]

    Unknown

  3. Jul 2024 — Sep 2024 [monthly]

    Unknown

    Status: Unknown Status → Unknown

  4. Mar 2022 — Jul 2024 [monthly]

    Unknown Status

    Status: Active Not Recruiting → Unknown Status

  5. Dec 2021 — Mar 2022 [monthly]

    Active Not Recruiting

▶ Show 11 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Active Not Recruiting

  2. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting

  3. Feb 2020 — Nov 2020 [monthly]

    Active Not Recruiting

  4. Mar 2019 — Feb 2020 [monthly]

    Active Not Recruiting

    Status: Recruiting → Active Not Recruiting

  5. Jun 2018 — Mar 2019 [monthly]

    Recruiting

  6. May 2018 — Jun 2018 [monthly]

    Recruiting

  7. Apr 2018 — May 2018 [monthly]

    Recruiting

    Phase: NA → None

  8. Mar 2018 — Apr 2018 [monthly]

    Recruiting NA

  9. Aug 2017 — Mar 2018 [monthly]

    Recruiting NA

  10. Apr 2017 — Aug 2017 [monthly]

    Recruiting NA

  11. Jan 2017 — Apr 2017 [monthly]

    Recruiting NA

    First recorded

May 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Centro Nacional de Investigaciones Oncologicas CARLOS III
Data source: Centro Nacional de Investigaciones Oncologicas CARLOS III

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

A Coruña, Spain , Barcelona, Spain , Ciudad Real, Spain , Córdoba, Spain , Granada, Spain , Guadalajara, Spain , Jerez de la Frontera, Spain , L'Hospitalet de Llobregat, Spain , Madrid, Spain , Manresa, Spain and 9 more locations